Shiraishi Y, Kishimoto J, Shimose T, Toi Y, Sugawara S, Okamoto I

Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non-small cell lung cancer patients with impaired renal function: RESTART trial.

BMC Cancer 22(1): 964, 2022Pubmed

Shiraishi Y, Shimose T, Tsuchiya-Kawano Y, Ishii H, Daga H, Ito K, Saruwatari K, Okamoto I

Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases.

Cancer Manag Res 14: 3449-3453, 2022Pubmed

Shiraishi Y, Hakozaki T, Nomura S, Kataoka T, Tanaka K, Miura S, Sekino Y, Ando M, Horinouchi H, Ohe Y, Okamoto I

A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study).

Clin Lung Cancer 23(4): e285-e288, 2022Pubmed

Iwama E, Zenke Y, Sugawara S, Daga H, Morise M, Yanagitani N, Sakamoto T, Murakami H, Kishimoto J, Matsumoto S, Nakanishi Y, Goto K, Okamoto I

Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations.

Eur J Cancer 162: 99-106, 2022Pubmed

Otsubo K, Kishimoto J, Ando M, Kenmotsu H, Minegishi Y, Horinouchi H, Kato T, Ichihara E, Kondo M, Atagi S, Tamiya M, Ikeda S, Harada T, Takemoto S, Hayashi H, Nakatomi K, Kimura Y, Kondoh Y, Kusumoto M, Ichikado K, Yamamoto N, Nakagawa K, Nakanishi Y, Okamoto I

Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial.

Eur Respir J 60(6): 2200380, 2022Pubmed

Tanaka K, Chamoto K, Saeki S, Hatae R, Ikematsu Y, Sakai K, Ando N, Sonomura K, Kojima S, Taketsuna M, Kim YH, Yoshida H, Ozasa H, Sakamori Y, Hirano T, Matsuda M, Hirai T, Nishio K, Sakagami T, Fukushima M, Nakanishi Y, Honjo T, Okamoto I

Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer.

Sci Transl Med 14(675): eabq0021, 2022Pubmed

Ibusuki R, Yoneshima Y, Hashisako M, Matsuo N, Harada T, Tsuchiya-Kawano Y, Kishimoto J, Ota K, Shiraishi Y, IwamaE, Tanaka K, Oda Y, Okamoto I

Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer.

Transl Lung Cancer Res 11(11): 2208-2215, 2022Pubmed

Ninomiya T, Otsubo K, Hoshino T, Shimokawa M, Nakazawa M, Sato Y, Mikumo H, Kawakami S, Mizusaki S, Mori Y, Arimura H, Tsuchiya-Kawano Y, Inoue K, Uchida Y, Nakanishi Y

Risk factors for disease progression in Japanese patients with COVID-19 with no or mild symptoms on admission.

BMC Infect Dis 21(1): 850, 2021Pubmed

Tsuchiya-Kawano Y, Shiraishi Y, Kiyomi F, Okamoto I

Phase II Study of Nivolumab Plus Ipilimumab with Platinum-Based Chemotherapy for Treatment-Naive Advanced Non-Small Cell Lung Cancer with Untreated Brain Metastases: NIke Trial (LOGiK2004).

Cancer Manag Res 13: 8489-93, 2021Pubmed

Tanaka K, Asahina H, Kishimoto J, Miyata Y, Uchida T, Watanabe K, Hamai K, Harada T, Tsubata Y, Sugawara S, Kobayashi K, Sugio K, Oisumi S, Okamoto I

Osimertinib Versus Osimertinib Plus Chemotherapy for Non-Small Cell Lung Cancer with EGFR (T790M)-Associated Resistance to Initial EGFR Inhibitor Treatment: An Open-Label, Randomized Phase 2 Clinical Trial.

Eur J Cancer 149: 14-22, 2021Pubmed

Yoneshima Y, Morita S, Ando M, Nakamura M, Iwasawa S, Yoshioka H, Goto Y, Takeshita M, Harada T, Hirano K, Oguri T, Kondo M, Miura S, Hosomi Y, Kato T, Kubo T, Kishimoto J, Yamamoto N, Nakanishi Y, Okamoto I

Phase 3 trial comparing nab-paclitaxel with docetaxel for previously treated advanced non-small cell lung cancer.

J Thorac Oncol 16(9): 1523-32, 2021Pubmed

Furukawa R, Inoue H, Yoneshima Y, Tsutsumi H, Iwama E, Ikematsu Y, Ando N, Shiraishi Y, Ota K, Tanaka K, Nakanishi Y, Okamoto I.

Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non-small cell lung cancer.

Lung Cancer 155: 144-50, 2021Pubmed

Liu R, Ota K, Iwama E, Yoneshima Y, Tanaka K, Inoue H, Tagawa T, Oda Y, Mori M, Nakanishi Y, Okamoto I.

Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non-small cell lung cancer patients treated with osimertinib.

Lung Cancer 158: 156-61, 2021Pubmed

Yoneshima Y, Iwama E, Matsumoto S, Matsubara T, Tagawa T, Ota K, Tanaka K, Takenoyama M, Okamoto T, Goto K, Mori M, Okamoto I

Paired analysis of tumor mutation burden for lung adenocarcinoma and associated idiopathic pulmonary fibrosis.

Sci Rep 11(1): 12732, 2021Pubmed

Inoue H, Tsutsumi H, Tanaka K, Iwama E, Shiraishi Y, Hirayama A, Nakanishi T, Ando H, Nakajima M, Shinozaki S, Ogata H, Uryu K, Okamura K, Kimura S, Ogawa T, Ota K, Yoneshima Y, Hamada N, Nakanishi Y, Okamoto I

Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer.

Transl Lung Cancer Res 10(6): 2475-86, 2021Pubmed

Iwama E, Sakai K, Hidaka N, Inoue K, Fujii A, Nakagaki N, Ota K, Toyozawa R, Azuma K, Nakatomi K, Harada T, Hisasue J, Sakata S, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I

Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors.

Cancer 126(1): 219-27, 2020Pubmed

Otsubo K, Iwama E, Ijichi K, Kubo N, Yoneshima Y, Inoue H, Tanaka K, Osoegawa A, Tagawa T, Nakanishi Y, Okamoto I

Paired genetic analysis by next-generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis.

Cancer Sci 117(7): 2482-7, 2020Pubmed

Shiraishi Y, Kishimoto J, Tanaka K, Sugawara S, Daga H, Hirano K, Azuma K, Hataji O, Hayashi H, Tachihara M, Mitsudomi T, Seto T, Nakagawa K, Yamamoto N, Okamoto I

Treatment rationale and design for APPLE (WJOG11218L): a multicenter, open-label, randomized phase 3 study of Atezolizumab and platinum/pemetrexed with or without Bevacizumab for patients with advanced nonsquamous non-small-cell lung cancer.

Clin Lung Cancer 21(5): 472-6, 2020Pubmed

Okamoto I, Nokihara H, Nomura S, Niho S, Sugawara S, Horinouchi H, Azuma K, Yoneshima Y, Murakami H, Hosomi Y, Atagi S, Ozaki T, Horiike A, Fujita Y, Okamoto H, Ando M, Yamamoto N, Ohe Y, Nakagawa K

Carboplatin-Pemetrexed Followed by Maintenance Pemetrexed Compared with Docetaxel Monotherapy in Elderly Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer: a Phase 3 Randomized Clinical Trial (JCOG1210/WJOG7813L).

JAMA Oncol 6(5): e196828, 2020Pubmed

Ikematsu Y, Tanaka K, Toyokawa G, Ijichi K, Ando N, Yoneshima Y, Iwama E, Inoue H, Tagawa T, Nakanishi Y, Okamoto I

NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration.

Lung Cancer 146: 97-104, 2020Pubmed

Iwama E, Goto Y, Murakami H, Tsumura S, Sakashita H, Mori Y, Nakagaki N, Fujita Y, Seike M, Bessho A, Ono M, Nishitsuji M, Akamatsu H, Morinaga R, Akagi T, Shimose T, Tokunaga S, Yamamoto N, Nakanishi Y, Sugio K, Okamoto I

Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401.

Oncologist 25(4): 306-e618, 2020Pubmed

Tsuchiya-Kawano Y, Sasaki T, Yamaguchi H, Hirano K, Horiike A, Satouchi M, Hosokawa S, Morinaga R, Komiya K, Inoue K, Fujita Y, Toyozawa R, Kimura T, Takahashi K, Nishikawa K, Kishimoto J, Nakanishi Y, Okamoto I

Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer.

Oncologist 25(6): 475-e891, 2020Pubmed

Ando N, Tanaka K, Otsubo K, Toyokawa G, Ikematsu Y, Ide M, Yoneshima Y, Iwama E, Inoue H, Ijichi K, Tagawa T, Nakanishi Y, Okamoto I

Association of Mps one binder kinase activator 1 (MOB1) expression with poor disease-free survival in individuals with non-small cell lung cancer.

Thorac Cancer 11(10): 2830-9, 2020Pubmed